top of page
Palm House interior _ RBG Kew (3)-13


Executive Team

Picture 1.jpg
  • LinkedIn

Prof Monique Simmonds OBE


Deputy Director of  Science at Kew Gardens, 30 years' experience of research into different aspects of plant and fungal chemistry with an emphasis on the economic value of natural products

  • LinkedIn

Prof Clare Bryant FBPhS


Professor of Innate Immunity  at University of Cambridge. A Fellow of the American Academy of Microbiology. Expertise in inflammation, infection and
anti-inflammatory pharmacology.  

Experience at Genentech, GSK

Lee Harle.jpg
  • LinkedIn

Lee Harle


More than 25 years (18 in APAC) building businesses & joint-ventures in consumer goods, technology and
life-science industries. Experienced commercial, CMO, M&A, strategy and global business leader.

AK headshot7.jpg
  • LinkedIn

Adam Kelliher


More than 20 years in Life Sciences, taking companies from inception to high value. Founded, built and sold Equazen Ltd (to Galenica) and Equateq Ltd (to BASF). CEO of NASDAQ-listed Avita Medical plc (regenerative medicine). PE/VC advisor.

Advisory Board

Picture a.jpg
  • LinkedIn

Prof Luke O’Neill

Professor of biochemistry at Trinity College Dublin Pioneering discoveries in immunity and immuno-metabolism
Co-founded Inflazome (acq by Roche)
& Sitryx

Picture h.jpg
  • LinkedIn

Prof Duncan Maskell

Vice-Chancellor University of Melbourne, former Pro-Vice Chancellor University of Cambridge and Professor Farm Animal Health, Food Science and Food Safety, University of Cambridge.


Royal Botanic Gardens, Kew

Founded 264 years ago, the Royal Gardens, Kew is an internationally recognised botanical research and education institution, employing 1,100 staff. Kew holds the world’s largest plant and fungi extract libraries, and has significant in-house expertise and capabilities to progress scientific discovery in the botanical world. Its stated purpose is to help stop biodiversity loss and develop nature-based solutions to some of humanity’s biggest global challenges.


Kew is a shareholder in Polypharmakos.

Cambridge University

Founded in 1209, Cambridge University is one of the world’s top centres for advanced science and technology, employing over 12,000 people. This ecosystem of world class scientists and academics has led to the development of many successful companies, resulting in Cambridge being the top commercial bioscience hub in Europe.  Polypharmakos is connected to the Departments of Medicine and Veterinary Medicine which have the cutting edge expertise for scientific discovery and identifying novel therapeutic candidates.

Cambridge Enterprise is a shareholder in Polypharmakos.


The Centre for Agriculture and Bioscience International is a global not-for-profit organization with 49 member countries who all work to improve people’s lives by applying scientific expertise to solve problems in agriculture and the environment. CABI’s fungal collection holds some 30,000 living microbes, representing 6000 species.  The collection, founded in 1947, has grown over the last 75 years to become one of the most important repositories with respect to agriculture and the environment, from unique environments around the world.  CABI has developed novel cryopreservation technology, to ensure the organisms are optimally maintained.

Images courtesy of Royal Botanic Gardens, Kew

Site Creative.jpg
Have a question?

If you would like to know more about Polypharmakos, please message us on our contact page

bottom of page